HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Verdi J. DiSesa Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DiSesa, V. J. Search for Related Content PubMed PubMed Citation Articles by DiSesa, V. J.

Ann Thorac Surg 1997;64:1858-1865
© 1997 The Society of Thoracic Surgeons

---

Current Reviews

Cardiac Xenotransplantation

Department of Cardiothoracic Surgery, Allegheny University Hospital, MCP, Philadelphia, Pennsylvania

Heart failure is an important medical and public health problem. Although medical therapy is effective for many people, the only definitive therapy is heart transplantation, which is limited severely by the number of donors. Mechanical devices presently are used as "bridges" to transplantation. Their widespread use may solve the donor shortage problem, but at present, mechanical devices are limited by problems related to blood clotting, power supply, and foreign body infection. Cardiac xenotransplantation using animal donors is a potential biologic solution to the donor organ shortage. The immune response, consisting of hyperacute rejection, acute vascular rejection, and cellular rejection, currently prevents clinical xenotransplantation. Advances in the solution of these problems have been made using conventional immunosuppressive drugs and newer agents whose use is based on an understanding of important steps in xenoimmunity. The most exciting approaches use tools of molecular biology to create genetically engineered donors and to induce states of donor and recipient bone marrow chimerism and tolerance in xenogeneic organ recipients. The successful future strategy may use a combination of a genetically engineered donor and a chimeric recipient with or without nonspecific immunosuppressive drugs.

This article has been cited by other articles:

				K. A. Hosiawa, H. Wang, M. E. DeVries, B. Garcia, W. Liu, D. Zhou, A. Akram, J. Jiang, H. Sun, M. J. Cameron, et al. CD80/CD86 Costimulation Regulates Acute Vascular Rejection J. Immunol., November 1, 2005; 175(9): 6197 - 6204. [Abstract] [Full Text] [PDF]

				J. Platt, V. DiSesa, D. Gail, and J. Massicot-Fisher Recommendations of the National Heart, Lung, and Blood Institute Heart and Lung Xenotransplantation Working Group Circulation, August 27, 2002; 106(9): 1043 - 1047. [Abstract] [Full Text] [PDF]

				M. Murtra The adventure of cardiac surgery Eur. J. Cardiothorac. Surg., February 1, 2002; 21(2): 167 - 180. [Full Text] [PDF]

				C. C. Canver and J. Chanda Heart transplantation Ann. Thorac. Surg., August 1, 2001; 72(2): 658 - 660. [Full Text] [PDF]

				R. M. El Oakley, O. C. Ooi, A. Bongso, and M. H. Yacoub Myocyte transplantation for myocardial repair: a few good cells can mend a broken heart Ann. Thorac. Surg., May 1, 2001; 71(5): 1724 - 1733. [Abstract] [Full Text] [PDF]

				E. Chinchoy, C. L. Soule, A. J. Houlton, W. J. Gallagher, M. A. Hjelle, T. G. Laske, J. Morissette, and P. A. Iaizzo Isolated four-chamber working swine heart model Ann. Thorac. Surg., November 1, 2000; 70(5): 1607 - 1614. [Abstract] [Full Text] [PDF]